Dental Tribune United Kingdom Edition

17Perio TribuneSeptember 10-16, 2012United Kingdom Edition page 18DTà Astra Tech Ltd Tel: 0845 450 0586 Fax: 01453 791001 Web: www.astratechdental.co.uk Email: atlantisabutments@astratech.com Atlantis™ crown abutment is an efficient, effective and aesthetic alternative to traditional cast abutments for single-tooth, screw-retained restorations. Like Atlantis™ patient-specific CAD/CAM abutments for cement-retained restorations, the Atlantis crown abutment is uniquely designed from the final tooth shape for more natural aesthetic results and available for all major implant systems. It is also precision-milled from a solid blank of biocompatible zirconia, which eliminates the need to cast with precious metals. What’s more, because porcelain is applied directly to the Atlantis crown abutment, it can be easily retrieved, if needed, and the time and cost of preparing a separate coping is recaptured. Atlantis crown abutment is available in five shades, including a new translucent zirconia in white. It can be placed in all positions in the mouth and is covered by a comprehensive warranty. For more on the benefits of Atlantis™ screw- and cement- retained solutions, visit www.astratechdental.co.uk. Experience the freedom of unlimited possibilities. Experience Atlantis™ . Discover Atlantis™ crown abutment fect results in slow, continued release of the active ingredi- ent in sufficient concentrations over a period of at least 12 days. Thanks to the bioresorbable nature of the product, the pa- tient does not require a further appointment and also benefits from relatively low systemic doxycycline exposure. Following Dr. Shalaby’s de- tailed look at the advantages of the innovative slow release gel formula, Professor Peter Eickholz, from the University of Frankfurt, Germany, con- tinued with the question of the effect to be expected following adjunctive administration of the new doxycycline gel. He began by listing the indications for local antibiotic therapy and continued with the results of clinical studies, which he used to present scientific evidence for the additional benefits of 14% SRD gel. In combination with SRP in the case of previ- ously untreated periodontitis, this has been proven to lead to improved attachment as well as greater pocket reduction that is clinically more relevant than achieved by SRP alone (Eickholz et al., 2002). A com- parison of sub-gingival, topical administration of antibiotics and mechanical debridement has shown comparable clini- cal efficiency (Eickholz et al., 2005). The primary benefits in the case of any residual deep pockets during SPT (Tonetti et al., 2012) had already been discussed in Professor Lang’s presentation. In his conclusion, Professor Eickholz emphasised a further feature of doxycy- cline: not only does it have an antibacterial effect, it is also anti-inflammatory. Clinical studies have also shown that once-off application of a 14% SRD gel in patients with peri- odontal disease reduces the presence of certain periodontal pathogenic bacteria in the sub- gingival plaque. Risk-based follow-up ensures long-term therapy success The second event on Friday evening focussed on current therapy options in periodontal treatment. In the first presen- tation, Professor Petra Ratka- Krüger from the University of Freiburg, Germany, looked at supportive periodontal therapy in daily practice, underlining the importance of SPT in long- term therapeutic success. She based her conclusions on a variety of studies, all of which provide scientific evidence of the positive impact when pa- tients with periodontal disease are treated regularly and con- sistently using SPT techniques. Based on a risk assessment at various levels (Lang & Tonetti, 2003), an individual risk analy- Briefing the assembled press The press breakfast Prof Ratka-Kruger